Results 51 to 60 of about 760 (154)

Epidemiology and clinical significance of carbapenemases in Australia: a narrative review

Internal Medicine Journal, Volume 54, Issue 4, Page 535-544, April 2024.
Abstract Carbapenemase‐producing gram‐negative bacteria (CP‐GNB) infections threaten public health with high mortality, morbidity and treatment costs. Although frequencies remain low in Australia (total number of CP‐GNB infections reported was 907 in 2022), blaIMP‐4 has established low levels of endemicity in many states.
Abdullah Tarik Aslan, David L. Paterson
wiley   +1 more source

New treatment options for multiresistant gram negatives [PDF]

, 2020
PURPOSE OF REVIEW: Multidrug-resistant (MDR) Gram-negative bacteria infections are listed among the top public health threats of the current era. As a result, there has been an increase in efforts to develop new therapeutic agents against MDR Gram ...
Isler, Burcu, Stewart, Adam, Paterson, David L.   +2 more
core   +1 more source

In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations [PDF]

Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. represent major threats and have few approved therapeutic options. Non-fermenting Gram-negative isolates were collected from hospitalized inpatients from 49 sites in 6 European countries ...
Dubois, Véronique, Corvec, Stephane, Leyssene, David, Willinger, Birgit, Casey, Anna, Pitart, Cristina, Hontangas, Jose Lopez, ARTEMIS Study Investigators: Willinger, Birgit, Marchese, Anna, Giammanco, Anna, Matinato, Caterina, Stefani, Stefania, Oliver, Antonio, Pletz, Mathias, Lopez, Alicia Beteta, Ziesing, Stefan, Coyne, Michael, Morrissey, Ian, Wareham, David, Lopez-Cerero, Lorena, Naas, Thierry, Cercenado, Emilia, Gontier, Audrey Merens, Gatermann, Sören, Perry, John, D, Santerre Henriksen, Anne, Bou, German, Jeannot, Katy, Raponi, Giammarco, null, null, Hughes, Daniel, Gracia-Ahufinger, Irene, Arena, Fabio, Lister, Michelle, Pletz, Mathias W., Lavigne, Jean-Philippe, Jung, Jette, Bianco, Gabriele, Rohde, Holger, Barrios, Jose, Luis, Cattoen, Christian, Boyer, Pierre, Barrios, Jose Luis, Perry, John, Domenico, Enea Gino Di, Canton, Rafael, Pletz, Mathias, W, Longshaw, Christopher, Nahl, Jasvir, Hunfeld, Klaus-Peter, Niccolai, Claudia, Gaibani, Paolo, Perry, John D., Alauzet, Corentine, Guillard, Thomas, Gontier, Audrey, Merens, Larrosa, Nieves, Carcione, Davide, Attwood, Marie, Imirzalioglu, Can, Domenico, Enea, Gino Di, Lopez, Alicia, Beteta, Hontangas, Jose, Lopez   +62 more
core   +5 more sources

P-1215. In vitro activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates from wound and urinary tract sources: ACNBio Study 2023-2025 [PDF]

Open Forum Infect Dis
Background Acinetobacter baumannii most often causes nosocomial bacteremia and pneumonia. However, A. baumannii is becoming an important cause of a broader range of infections including skin and soft tissue infection (SSTI) and urinary tract infections ...
Kirn, Thomas, Chavez, Violeta, Westblade, Lars, Mutnal, Manohar B, Potula, Raghava, Daniels, Anne R, Pierce, Virginia M, Beck, Eric T, Narayanan, Navaneeth, Simner, Patricia J, Cyr, Elizabeth, Fisher, Mark, Argotsinger, Jill, Dumm, Rebekah, Gialanella, Philip, Kufel, Wesley D, Chamberland, Robin R, Marino, Jamie, Huse, Holly, Abbo, Lilian M, Hamilton-Seth, Robert, Riddell, Scott W, Jenkins, Timothy C, Harrington, Amanda, Asempa, Tomefa E, Hankins, Julia, Tibbetts, Robert, Vu, Christine A, Tekle, Tsigereda, Humphries, Romney, Clark, Andrew E, Mochon, Brian, Nicolau, David P, Martinez, Octavio, Hand, Jonathan, Liesman, Rachel   +35 more
europepmc   +2 more sources

Comparative <i>in vitro</i> activity of sulbactam with avibactam or durlobactam against carbapenem-resistant <i>Acinetobacter baumannii</i>. [PDF]

JAC Antimicrob Resist
Abstract Objective To determine the in vitro activity of sulbactam in combination with avibactam or durlobactam with and without meropenem or imipenem against carbapenem-resistant Acinetobacter baumannii clinical isolates.
Dorazio AJ, Kline EG, Squires KM, Griffith MP, Doi Y, Shields RK.   +5 more
europepmc   +3 more sources

Sulbactam-durlobactam improves cephalosporin and carbapenem susceptibility and time-kill effect against <i>Mycobacterium abscessus</i>. [PDF]

Microbiol Spectr
ABSTRACT Despite the long therapy duration, the treatment outcomes for Mycobacterium abscessus lung disease (MAB-LD) are very poor. β-Lactams are among the recommended drugs for the treatment of MAB-LD; however, they are prone to hydrolysis by MAB β-lactamase enzymes ...
Shrivastava A, Boorgula GD, Singh S, Stiles D, McShane PJ, Devine M, Devine M, Gumbo T, Srivastava S.   +8 more
europepmc   +3 more sources

Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases [PDF]

The relative inhibitory activities of diazabicyclooctanes (avibactam, relebactam, zidebactam, nacubactam, durlobactam), boronic acid derivatives (vaborbactam, taniborbactam, xeruborbactam), and penicillin-based sulfone derivative enmetazobactam were ...
Le Terrier, Christophe, Sadek, Mustafa, Mlynarcik, Patrik, Nordmann, Patrice, Poirel, Laurent   +4 more
core   +1 more source

Case report: Successful treatment of OXA-23 neurosurgical infection and meningitis with sulbactam-durlobactam combination therapy [PDF]

Meningitis caused by species is a rare complication of neurosurgical procedures, although it is associated with high morbidity and mortality. Carbapenem-resistant is particularly difficult to treat, considering the limited selection and tolerability of
Rawlings, Stephen A, Snowdin, Jacob W, Madaio, Michael P, Mercuro, Nicholas J   +3 more
core  

Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol : which are the best present and future therapeutic alternatives ? [PDF]

Purpose: To evaluate the different present and future therapeutic β-lactam/β-lactamase inhibitor (BL/BLI) alternatives, namely aztreonam-avibactam, imipenem-relebactam, meropenem-vaborbactam, cefepime-zidebactam, cefepime-taniborbactam, meropenem ...
Le Terrier, Christophe, Freire, Samanta, Nordmann, Patrice, Poirel, Laurent   +3 more
core   +1 more source

Population pharmacokinetic analyses for sulbactam–durlobactam using Phase 1, 2, and 3 data

Antimicrobial Agents and Chemotherapy
ABSTRACT Sulbactam–durlobactam is a β-lactam/β-lactamase inhibitor combination approved in the United States for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii–calcoaceticus in adults.
Anthony P. Cammarata, M. Courtney Safir, Michael Trang, Kajal B. Larson, John P. O'Donnell, Sujata M. Bhavnani, Christopher M. Rubino   +6 more
openaire   +2 more sources